Thymosin alpha 1 does not promote growth or oncogenic transformation.
Naylor. P H PH; Smith. M R MR; Mutchnick. M G MG; Naylor. C W CW; Dosescu. J J; Skunca. M M; Moshier. J A JA
Key Findings
- Adding Tα1 to cells did not increase tumor cell growth
- Cells engineered to overproduce Tα1 showed no extra proliferation or loss of contact inhibition
- Both external and internal Tα1 were not able to cause anchorage‑independent growth, a hallmark of transformation
Practical Outcomes
- For biohackers using Tα1 to boost immunity, the research suggests it’s unlikely to raise cancer risk, so no special safety limits are needed for oncogenic concerns. It can be incorporated into longevity or performance protocols without fearing growth‑promoting side effects.
Summary
The study shows that the peptide thymosin‑alpha‑1 (Tα1) does not make cancer cells grow faster or turn normal cells into cancer cells, whether it’s added from outside or made inside the cells themselves.
Abstract
Thymosin alpha 1 (T alpha 1) is an immune modulatory peptide which has been evaluated in a variety of clinical trials. Although no in vivo adverse effects, including enhancement of tumor growth, have been noted, in vitro studies suggesting a role for T alpha 1 in cell growth have been reported. The studies presented in this report evaluated both exogenously added T alpha 1 and endogenously expressed T alpha 1 as factors which could either promote growth of tumor cells or induce transformation. No effect of exogenous T alpha 1 on cell growth was found. NIH-3T3 cells transfected with cDNA for the precursor ProThymosin alpha (Pro T alpha) expressed elevated levels of authentic T alpha 1 but did not demonstrate either enhanced proliferation in liquid culture or transformation as defined by the loss of contact inhibition or anchorage independent growth in soft agar. Thus these studies argue against the hypothesis that T alpha 1 is either an intracellular or extracellular growth promoter.
Study Information
pubmed
1996
10.1016/0192-0561(96)00032-x